Literature DB >> 14680464

Stem cell therapy for muscular dystrophy.

Regina Lee Sohn1, Emanuela Gussoni.   

Abstract

Muscular dystrophy is a heterogeneous group of neuromuscular disorders that manifests as progressive muscle weakness, muscle wasting and, in many cases, death. Although there has been enormous progress in the molecular understanding of muscular dystrophy, there is still no cure. There are, however, several different therapeutic options under investigation, including adult-derived stem cell transplantation. Encouraging and pioneering experiments in mouse models for Duchenne's muscular dystrophy (DMD) demonstrated that myoblasts could be transplanted into dystrophic muscle; these myoblasts repaired a small proportion of damaged myofibres. Subsequent work has been devoted to optimisation of this technique. In doing so, a number of adult-derived stem cells have been isolated, characterised and used in promising animal transplantation experiments. Further research is ongoing, and is clearly necessary to make this therapy a viable treatment option for patients with muscular dystrophy.

Entities:  

Mesh:

Year:  2004        PMID: 14680464     DOI: 10.1517/14712598.4.1.1

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  8 in total

1.  Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods.

Authors:  Jesse V Jokerst; Mridhula Thangaraj; Paul J Kempen; Robert Sinclair; Sanjiv S Gambhir
Journal:  ACS Nano       Date:  2012-06-20       Impact factor: 15.881

2.  Fetal microchimeric cells in a fetus-treats-its-mother paradigm do not contribute to dystrophin production in serially parous mdx females.

Authors:  Elke Jane Seppanen; Samantha Susan Hodgson; Kiarash Khosrotehrani; George Bou-Gharios; Nicholas M Fisk
Journal:  Stem Cells Dev       Date:  2012-08-06       Impact factor: 3.272

3.  A Myogenic Double-Reporter Human Pluripotent Stem Cell Line Allows Prospective Isolation of Skeletal Muscle Progenitors.

Authors:  Jianbo Wu; Nadine Matthias; Jonathan Lo; Jose L Ortiz-Vitali; Annie W Shieh; Sidney H Wang; Radbod Darabi
Journal:  Cell Rep       Date:  2018-11-13       Impact factor: 9.423

4.  Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy.

Authors:  Terren K Niethamer; Tal Yardeni; Petcharat Leoyklang; Carla Ciccone; Adrian Astiz-Martinez; Katherine Jacobs; Heidi M Dorward; Patricia M Zerfas; William A Gahl; Marjan Huizing
Journal:  Mol Genet Metab       Date:  2012-10-18       Impact factor: 4.797

Review 5.  UDP-GlcNAc 2-Epimerase/ManNAc Kinase (GNE): A Master Regulator of Sialic Acid Synthesis.

Authors:  Stephan Hinderlich; Wenke Weidemann; Tal Yardeni; Rüdiger Horstkorte; Marjan Huizing
Journal:  Top Curr Chem       Date:  2015

Review 6.  Mesenchymal stem cell priming: fine-tuning adhesion and function.

Authors:  Dean P J Kavanagh; Joseph Robinson; Neena Kalia
Journal:  Stem Cell Rev Rep       Date:  2014-08       Impact factor: 5.739

7.  Stem cells from umbilical cord blood do have myogenic potential, with and without differentiation induction in vitro.

Authors:  Tatiana Jazedje; Mariane Secco; Natássia M Vieira; Eder Zucconi; Thomaz R Gollop; Mariz Vainzof; Mayana Zatz
Journal:  J Transl Med       Date:  2009-01-14       Impact factor: 5.531

8.  Volumetric muscle loss injury repair using in situ fibrin gel cast seeded with muscle-derived stem cells (MDSCs).

Authors:  Nadine Matthias; Samuel D Hunt; Jianbo Wu; Jonathan Lo; Laura A Smith Callahan; Yong Li; Johnny Huard; Radbod Darabi
Journal:  Stem Cell Res       Date:  2018-01-09       Impact factor: 2.020

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.